

20th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine 45th Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC)


Euromedlab 2013 Closes

Closing remarks

At the end of five intensive but fully enjoyable days we can state that the Euromedlab 2013 succeeded in delivering an extraordinary mixture of scientific information offered by outstanding speakers and more practical opportunities offered by Educational Workshops organized in cooperation with Diagnostic Companies. All this has been made possible by the joint efforts of a great number of people, who worked together during the Congress and for the three years before it. In particular, the contribution of the Organising Secretariat of MZ Congressi should be recognized, together with that of all the Colleagues

involved in the various Committees, i.e., the Congress Organising Committee, the Scientific Programme Committee, the Abstract Evaluation Committee, the Bursary and Poster Awards Committees and the International Scientific Advisory Board. Euromedlab Congresses have always been an extraordinary opportunity to meet friends and colleagues from all over the world and to exchange with them opinions and fruitful discussions. Milan 2013 made no exception and everybody working for that has to be thanked warmly.

Next Euromedlab meeting will be in Paris, 21-25 June 2015.



1. Plenary lecture on Molecular Basis and Clonal Evolution of Myeloproliferative Neoplasms: Prof. Robert Kralovics

TODAY'S PROGRAMME OVERVIEW

9:00 - 11:00 PARALLEL SYMPOSIA

- Room Gold
SYMPOSIUM 13
CONTROVERSIES IN DETECTION AND MONITORING OF DIABETES

- Room Silver
SYMPOSIUM 14
LABORATORY ASSESSMENT OF MATERNAL/FETAL UNIT

- Auditorium
SYMPOSIUM 15
LABORATORY TESTING IN BONE AND JOINT DISEASE

- Room Brown 3
SYMPOSIUM 16
EMERGING ISSUES IN SEPSIS

- Room Brown 1-2
SYMPOSIUM 17
LABORATORY MANAGEMENT AND PATIENT SAFETY

11:45 - 12:30 **PLENARY LECTURE**
Acute coronary syndrome: the present and future role of biomarkers
B. Lindahl (Sweden)

12.30 - 13:00 **CLOSING CEREMONY**

CONGRESS FIGURES

The success of the Congress can be measured also from the following figures.

The number of delegates attending for one or more days is **4.786** from **101 different Countries**. The delegates from outside Europe accounted for **20 %**. Attendees **younger than 35 years** of age were **393 (8%)**.

The **82 exhibitors** covered an **area of 3.500 m²**; the

exhibition area was visited by **more than 2.400 people** (beyond the delegates).

52 invited speakers contributed to the high scientific level of the **5 Plenary Sessions** and **23 Symposia**.

45 Educational Workshops have been organized in close cooperation with Diagnostic Companies.

The delegates presented **1239 posters**, 240 of which have been selected for the poster walks.

LAST CHANGES

9:00 - 11:00
Room Brown 1 - 2 SYM 17
Laboratory Management and Patient Safety
A. Simundic (Chair) is replaced by M. Plebani

ERRATA CORRIGE

The **TERMOFISHER** sponsored poster **T266** awarded on Tuesday is replaced by

T211
NONINVASIVE PRENATAL DIAGNOSIS OF CYSTIC FIBROSIS
S. Galbiati, A. Monguzzi, N. Soriani, F. Lalatta, M. Seia, F. Damin, M. Cretich, M. Chiari, M. Ferrari (Italy)

HOT SPOT IN LABORATORY MEDICINE

Ethics in Laboratory Medicine

Maria Stella Graziani

University-Hospital of Verona, Italy

Our profession is characterized by an important presence of technology and informatics: this has possibly induced us to perceive ethical issues as marginal. Actually, these points should be considered essential in Laboratory Medicine as it is in any other disciplines of human healthcare.

There are however unique ethical aspects in Clinical Chemistry and Laboratory Medicine that require particular attention. Among these:

The indirect patient contact: the relationship between the Clinical Biochemist and the patient is complicated by the fact that in most circumstances there isn't a direct contact with the patient but there is rather a contractual relationship between the requester and the laboratory. There is therefore the risk that this relationship (which is often commercial) could be seen as more relevant; however the laboratory's commitment is to ensure and pursue the interest and the well-being of the patient. The patient's wishes and needs are however very often conveyed to the laboratory not by the patient him/her self but rather by the patient's clinical caregivers. The Clinical Laboratory should carefully handle this kind of relationship and secure that the intermediary healthcare workers act within a similar ethical framework as Clinical Chemists do.

Storage and use of physical samples: A clinical laboratory may store aliquots of the

patient's primary samples for a number of reasons like internal quality control, instrument checks, method development, teaching and research.

These activities may result in additional information to which the patient may not have originally consented. Laboratories should have documented policies for handling unrequested information, considering legal implication and national or local requirements.

Another important issue shared with the entire scientific community is the publication ethics. The topic is so relevant that the Congress planned a Workshop on Publication Ethics held by the Clinical Chemistry Editor, to serve as a guide for young scientists both to scientific writing and to ethical conduct when preparing and submitting a paper to a journal.

Publication ethics can be defined as the correct conduct in the entire process of publication. This issue is emphasized today by the enormous number of scientific journals, by the easy access to the electronic databases which allow the consultation of even local journals, together with the career pressure (*publish or perish!*).

The Laboratory Medicine professional members should be guided by ethical principles in any facets of their work because of their responsibility towards patients and the scientific community they live and work in.

Information, Guidelines and Discussion on Ethics in Science and in Laboratory Medicine can be found at:

- 15189 ISO Annex C;
- IFCC position paper: Report of the IFCC Taskforce on Ethics: Introduction and framework. CCLM 2007;45:1098-1104.
- Council of Europe, Committee of Ministers, Recommendation Rec(2006)4 of the Committee of Ministers to member states on research on biological materials of human origin. <https://wcd.coe.int/ViewDoc.jsp?id=977859>
- WORLD MEDICAL ASSOCIATION: DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects. <http://www.wma.net/en/30publications/10policies/b3/17c.pdf>
- AACC Ethics guidelines. <http://www.aacc.org/members/Pages/ethics.aspx#>
- IFCC Ethics Task Force. Ethics in science: background and resources on publication ethics. Available at: <http://www.ifcc.org/media/161822/IFCC%20Ethics%20in%20Science.pdf>
- European EC4/EFLM Code of Conduct. <http://efcclm.eu/profession/code-of-conduct>



Society Name Change:

"SIBioC - Laboratory Medicine"

(The Italian Society of Clinical Biochemistry and Clinical Molecular Biology)

During its most recent general assembly on April 15, 2013, an amendment to the scientific society's by-laws was ratified by the board and the full membership. While leaving the glorious **SIBioC** acronym unchanged, they changed the society's name to

"SIBioC - Laboratory Medicine"

(The Italian Society of Clinical Biochemistry and Clinical Molecular Biology)

As with the previous change that led the **IFCC** to become the "**international federation of clinical chemistry and Laboratory Medicine**", this change responds to

a recommendation from the European Federation of Clinical Chemistry and Laboratory Medicine (**EFLM**) inviting all members to start including laboratory medicine in their title.

This request is the logical consequence of last year's decision by EFLM member societies on the most appropriate descriptive name for our profession: "**specialists in laboratory medicine**". This is the first stage in a two-step process to enable us to progress toward recognition of the profession under a European common-training framework.

Acute coronary syndromes – The present and future role of biomarkers

Bertil Lindahl

M.D., Ph.D., Uppsala Clinical Research center and department of medical sciences, Uppsala University, Sweden



Over the past two decades there have been dramatic changes in the diagnosis, treatment and prognosis of acute coronary syndromes (ACS). Several new treatment modalities have been added. The prognosis after acute myocardial infarction (AMI) has improved, e.g. the 30 day mortality has been more than halved the last decade.

Biomarkers have crucial roles in the management of ACS: for diagnosis as well as for prognosis and selection of treatment. At present, cardiac troponin (cTn) is the biomarker of choice for diagnosis of AMI. Currently, there are no other biomarkers, especially after the introduction of the high sensitivity assays, which can compete, neither regarding specificity nor regarding early sensitivity. However, there is still a clinical need

of a biomarker able to reliably rule-in or rule-out AMI, immediately on admission. Secondly, a marker able of separating type I from type II infarctions would be clinically very useful. Thirdly, for the diagnosis of unstable angina a biomarker of cardiac ischemia is needed. MicroRNAs seem to be the most promising new candidates for diagnostic purposes. The optimal combination of biomarkers and new imaging techniques is another important area for research.

The list of biomarkers associated with an adverse prognosis in ACS is long. However, for most of them it has been very difficult to prove an added clinical value. Only cTn, and to some degree also B-type natriuretic peptides, is widely used in clinical practice for risk assessment. Among new markers, growth differentiation factor 15 and the

mid-regional part of the prohormone of adrenomedullin, have shown some promising results. The importance of moderate decrease in renal function for the prognosis has been much overlooked in the past. And since the renal function must be assessed anyway, i.e. for correct dosing of many drugs, it seems logical to utilize also the prognostic capacity of markers of the renal function.

Cardiac troponin has been proven useful for selection of antithrombotic, antiplatelet and invasive treatment. Besides cTn, no other markers have consistently been shown to be useful for selection of specific treatments. However, in the predicted future era of “personalized medicine”, new biomarkers for selection of treatments are much needed.

NEWS FROM MIDDLE EAST

ISRAEL EXPANDS GAZA FISHING ZONE AND STOPPED THE VISIT OF UNESCO

GAZA - Israel announced an expansion of the designated fishing zone off Gaza from 3 to 6 nautical miles in the Mediterranean Sea. The move was approved by Israeli Prime Minister Binyamin Netanyahu and Defense Minister Moshe Ya'alon. Israel restricted the designated fishing zone in March in response to rocket attacks on southern Israel. The Oslo Accords between Israel and the Palestinians

in 1993 stipulated that Israel would permit a 20-nautical mile fishing zone off Gaza. Again Israel, at the last minute, postponed the visit of a Unesco delegation to Jerusalem's Old City. “The visit of the Unesco mission is a preface for the victory of Palestinian and Arab diplomacy,” a newspaper said, quoting a statement from the Palestinian Ministry of Information in Ramallah.



NEWS FROM EUROPE

CHAMPIONS LEAGUE FINAL: IS FUSSBALL COMING HOME?

With Borussia Dortmund playing Bayern Munich in the Champions League final on Saturday, thousands of German fans will be heading to the home of English football, Wembley. But is it also the home of German football? “Fussball is coming home” ran the headline in the Bavarian-based Sueddeutsche Zeitung early in May.



NEWS FROM AFRICA

NIGERIA TO FREE “TERROR” WOMEN

Nigeria's President Goodluck Jonathan has ordered the release of all women held in connection with “terrorist activity”, the defence ministry says. The decision was aimed at enhancing peace efforts in Nigeria, it added. The army is conducting an offensive in th-

ree states, where an emergency was declared last week to fight the militant Islamist group Boko Haram. The group had set the release of women and children as a condition for talks with the government. More than 2,000 people have died in

the conflict in Nigeria since Boko Haram launched its insurgency in 2009 to create an Islamic state. Earlier this month, it said it had abducted women and teenage girls in response to the security forces arresting the relatives of its fighters.

NEWS FROM WORLD

IS THE CANNES FILM FESTIVAL STILL NUMBER ONE?

It has glamour, history and tons of media hype – but is Cannes still the best



place to launch a new film? It's been called the stairway to heaven – the red-carpeted steps leading up to the Palais des Festivals at Cannes where top directors and stars congregate each night. It is one of the most media-saturated spaces on Earth, making Cannes a particularly desirable platform for the big studios. Last year four thousand journalists were accredited to cover the

festival; forty years ago there were just over a quarter of that amount. What the festival can do to bring attention to a film is perhaps unbeatable. But as a marketing machine Cannes is not without its perils – a spanner can easily get thrown into the works.

The festival can amplify a film's perceived weaknesses and any harsh critical comment that surrounds it. It is sort of a double-edged sword.

It will all leave Karl Planck turning in his grave. In the 1890s, this German gymnast and patriotic teacher raged against the “foot-louts” in Germany suffering from what was called “the English disease”.

They were playing a new game, football, imported from Britain. The sport was, Planck wrote, “absurd, ugly and perverted”. Planck hoped that Germans would stick to gymnastics, seen as better at producing young men fit for military service. But the thousands of today's Germans heading for Wembley Saturday will prove that Planck failed and British sport triumphed.

CULTURAL AND SOCIAL EVENING

The Cultural and Social Evening at the Castello Sforzesco yesterday night was an extraordinary experience. The participants could enjoy the site's special atmosphere and partake of a luscious buffet. There also was the opportunity to visit the Castle Museums open until late for Euromedlab guests. Of particular interest was the possibility to admire the Michelangelo's statue named "Pietà Rondanini" (by the name of one of its owner).



The Castello Sforzesco - Photo by Roberto Tomei



The "Pietà Rondanini"

At the end of the evening, the show of the Flying Acrobats "Sonics" in the "Piazza delle Armi" was simply breathtaking.




The luscious buffet



The "Sonics"





POSTERS AWARDS

Monday 20 May

SPONSORED BY SIBioC

M003

EOTAXIN-2 (CCL24) and EOTAXIN-3 (CCL26) LEVELS IN NASAL LAVAGE OF PATIENTS WITH EOSINOPHILIC CHRONIC INFLAMMATION
E. De Corso, R. Penitente, M. Romanelo, M. Battista, G. Paludetti, C. Zuppi, S. Baroni (Italy)

M054

DIAGNOSIS OF CONRADI-HÜNERMANN-HAPPLE SYNDROME: CHOLESTEROL INTERMEDIATES MEASUREMENT, GENETIC TESTING AND HISTOLOGY NEED TO BE ASSOCIATED
K. Belabbas, A. Lamazière, S. Leclerc-Mercier, F. Chevy, S. Schmitt, J. Martinovic, A. Liquier, R. Mangione, A. Domp Martin, M. Barreau, J. Masliah, S. Hadj-Rabia, F. Dufernez (France)

M072

BBS1, BBS10 AND BBS2 ARE MAJOR CAUSATIVE GENES FOR BARDET-BIEDL SYNDROME IN ITALIAN PATIENTS
M. D'Antonio, G. Esposito, I. Tandurella, A. Crispo, F. Simonelli, V. Di Iorio, F. Salvatore (Italy)

M081

ATYPICAL CYSTIC FIBROSIS: DEVELOPED A NEW GENETIC TEST FOR IDENTIFICATION OF ENAC MUTATIONS
A. Renesto, K. Bortolozzo, A. Albanese, A. Tamanini, C. Zampieri, M. Dececchi (Italy)

M082

MOLECULAR ANALYSIS OF PATIENTS WITH ELEVATED LONG-CHAIN 3-OH-ACILCARNITINES ALLOWS DIFFERENTIAL DIAGNOSIS BETWEEN LCHAD AND MTP DEFICIENCY
C. Cozzolino, R. Romanelli, E. Scolamiero, G. Parenti, G. Andria, M. Ruoppolo, G. Frisso, F. Salvatore (Italy)

M098

EVALUATION OF PRESEPSIN (sCD14-ST) IN CORD BLOOD AS A MARKER FOR EARLY-ONSET NEONATAL SEPSIS
I. Cebreiros-López, J. Noguera-Velasco, A. Martínez-Ruiz, N. Sancho-Rodríguez, I. De Miguel-Elizaga, M. Martínez-Villanueva, J. Vilchez-Aguilera, C. Puche-Morenila, P. Martínez-Hernández (Spain)

M109

IDENTIFYING DENV-1 B-CELL EPITOPES USING PHAGE DISPLAY TECHNIQUE
E. Kuusela, G. Batra, U. Lamminmäki (Finland)

M186

AFFINITY IMPROVEMENT OF A UNIQUE PSA ANTIBODY USING PHAGE DISPLAY TECHNOLOGY
M. Liton, E. Brockmann, M. Peltola, M. Vehniäinen, E. Kuusela, U. Lamminmäki, K. Pettersson (Finland)

M329

SIGNIFICANT DECREASE OF PLUMBEMIA IN LEAD-EXPOSED WORKERS DUE TO EFFECTIVE PREVENTIVE MEASURES
F. Los, L. Kotackova, T. Zima (Czech Republic)

M398

IDENTIFICATION OF THE SOLUBLE MANNOSE RECEPTOR IN HUMAN SERUM AS A NEW MACROPHAGE-RELATED BIOMARKER
S. Rodgaard-Hansen, A. Rafique, P. Christensen, M. Maniecki, T. Sandahl, E. Nexø, H. Møller (Denmark)

POSTERS AWARDS

Tuesday 21 May

SPONSORED BY BIOMEDIA

T048

A RAPID AND SELECTIVE METHOD FOR THE MEASUREMENT OF TESTOSTERONE IN HUMAN SERUM IN 10 SECONDS USING LASER DIODE

THERMAL DESORPTION-DIFFERENTIAL ION MOBILITY SPECTROMETRY-TANDEM MASS SPECTROMETRY (LDTD-DMS-MS/MS)
M. Jarvis, E. McClure, P. Picard, S. Auger, G. Blachon, J. Botelho, Y. Wang (Canada)

T116

SPIDIA-RNA: FIRST EXTERNAL QUALITY ASSESSMENT FOR THE PRE-ANALYTICAL PHASE OF BLOOD SAMPLES USED FOR RNA BASED ANALYSES
F. Malentacchi, L. Simi, C. Orlando, R. Wyrich, K. Guenther, C. Hartmann, P. Verderio, S. Pizzamiglio, C. Ciniselli, A. Tichopad, M. Kubista, S. Gelmini, M. Pazzagli (Italy)

T119

HOW TO PROCESS BLOOD SAMPLES FASTER IN A ROUTINE CLINICAL BIOCHEMISTRY LAB
C. Munch Jensen (Denmark)

T150

A SENSITIVE AND SELECTIVE LC-ION MOBILITY-MASS SPECTROMETRIC ANALYSIS OF ALLOPREGNANOLONE AND ITS ISOMERS IN HUMAN PLASMA OR SERUM
W. Jin, M. Jarvis, M. Weinstock, M. Altemus (USA)

T162

LOWER ENZYME ACTIVITIES OF METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) IN PATIENTS WITH FIRST EPISODE PSYCHOSIS AND SCHIZOPHRENIA INDEPENDENT OF MTHFR C677T AND A1298C MUTATIONS
T. Muftuoglu, O. Ozcan, O. Ipcioglu, A. Ates, M. Gultepe (Turkey)

SPONSORED BY THERMOFISHER

T171

DEVELOPMENT OF PRELIMINARY CUT-POINTS FOR PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER'S DEMENTIA FOR THE VITROS® AB-42 AND VITROS TAU IMMUNOASSAYS
H. Soares, I. Baburina, D. Kozo, S. Salamone, G. Green, L. DiMagno, P. Contestable, H. Zetterberg, K. Blennow (USA)

T192

LYMPHOCYTE SUBSETS AND ACTIVATION MARKERS IN CHILDREN WITH IMMUNODEFICIENCIES AND RECURRENT INFECTIONS
G. Pantano, F. Tosato, G. Bucciol, M. Putti, B. Barbin, G. Marangi, M. Sanzari, M. Plebani (Italy)

T211

NONINVASIVE PRENATAL DIAGNOSIS OF CYSTIC FIBROSIS
S. Galbiati, A. Monguzzi, N. Soriani, F. Lalatta, M. Seia, F. Damin, M. Cretich, M. Chiari, M. Ferrari (Italy)

SPONSORED BY IRIS INTERNATIONAL

T288

CELIAC DISEASE DIAGNOSIS AND MONITORING: COMPARISON BETWEEN CHEMILUMINESCENCE AND ELISA ANTITRANSGLUTAMINASE AND ANTI-DEAMIDATED GLIADIN PEPTIDES MEASUREMENTS
A. Aita, D. Basso, E. Rossi, M. Pelloso, G. Guariso, C. Zambon, F. Navaglia, E. Greco, D. Bozzato, A. Padoan, P. Fogar, M. Plebani (Italy)

T403

GENETICALLY ENCODED PROTEASE SUBSTRATE BASED ON LANTHANIDE-BINDING PEPTIDE FOR TIME-GATED FLUORESCENCE DETECTION
J. Vuojola, M. Syrjänää, U. Lamminmäki, T. Soukka (Finland)

POSTERS AWARDS

Wednesday 22 May

SPONSORED BY BINDING SITE

W136

ASSOCIATION OF SERIAL CHANGES IN GALECTIN-3 WITH ADVERSE CARDIOVASCULAR EVENTS IN AMBULATORY CHRONIC HEART FAILURE PATIENTS
A. Saenger, W. Miller, A. Lueke, D. Grill, A. Jaffe (USA)

W138

EVALUATION OF AUTOANTIBODY PREVALENCE IN PATIENTS WITH SUSPECTED MYOCARDIAL INFARCTION WITH IMPROVED IMMUNOASSAY FOR DETECTING AUTOANTIBODIES TO CARDIAC TROPONIN
T. Savukoski, P. Laaksonen, S. Wittfooth, T. Ilva, J. Lund, P. Porela, K. Pettersson (Finland)

W337

NEOPTERIN AND CALPROTECTIN: FECAL MARKERS FOR PREDICTING ENDOSCOPIC SEVERITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
C. Cuereq, J. Drai, E. Blond, A. Mialon, A. Charlois, B. Flourie, D. Kaiserlian, G. Boschetti, S. Nancey (France)

SPONSORED BY IL

W063

INTERLEUKIN-15, CORONARY ARTERY DISEASE AND EPICARDIAL ADIPOSE TISSUE: POSSIBLE CORRELATIONS
G. Dogliotti, E. Dozio, E. Vianello, G. Schmitz, M. Corsi Romanelli (Italy)

W260

AN EVALUATION OF IMMATURE GRANULOCYTE COUNT AS A BIOMARKER FOR POSTOPERATIVE INFECTION
K. Husby, S. Yaqub, M. Helgeland, O. Reiertsen, G. Kravdal, H. Eilertsen, T. Hagve (Norway)

SPONSORED BY EUROMEDLAB

W004

ASSESSMENT OF BONE TURNOVER MARKERS FOR THE EARLY DETECTION OF MYELOMA BONE DISEASE RELAPSE
J. Brady, A. Hameed, K. Ting, P. O'Gorman (Ireland)

W050

HIGH SENSITIVE CARDIAC TROPONIN T AND COPEPTIN ASSAYS IN THE MANAGEMENT OF PATIENTS PRESENTING WITH CHEST PAIN OF LESS THAN 6 HOURS
D. Collin-Chavagnac, J. Aupetit, T. Perret, G. Lefevre (France)

W180

BIOCHEMICAL AND PHENOTYPE IMPROVEMENT IN SEVERELY OBESE PATIENTS AFTER BARIATRIC SURGERY
L. Iaffaldano, C. Nardelli, D. Montanaro, M. Ferrigno, G. Labruna, N. Carlomagno, M. Santangelo, A. Renda, V. Pilone, A. Baldi, P. Forestieri, L. Sacchetti (Italy)

W366

BIOLOGIC VARIATION OF COPPER, CERULOPLASMIN AND COPPER/CERULOPLASMIN RATIO IN SERUM
D. Szöke, F. Braga, C. Valente, M. Panteghini (Italy)

SPONSORED BY ELAS

W242

SENSITIVITY FOR NON-TUMOR IMMUNOGLOBULIN SUPPRESSION IN IFE AND SPE POSITIVE MULTIPLE MYELOMA MONITORING SAMPLES BY HEVYLITE™ AND TOTAL IMMUNOGLOBULIN
L. Traylor, S. LeSourd, K. Sweat, B. Barlogie, S. Usmani, J. Bornhorst (USA)

CONGRESS BURSARIES

MILANO BURSARY PROGRAMME



EFLM BURSARIES

1. Calibasi Gizem (Turkey)
2. Canu Giulia (Italy)
3. Cardinaels Eline (Belgium)
4. Dunlop Allan (United Kingdom)
5. Elce Ausilia (Italy)
6. Hansson Charlotte (Sweden)
7. Isgrò Maria Antonietta (Italy)
8. Martínez López De Castro Ana María (Spain)
9. Min San (United Kingdom)
10. Oliveira Rodríguez Myriam (Spain)



EC4 BURSARIES

1. Rizou Myrto (Greece)
2. Wlazel Rafal N. (Poland)



A. MENARINI BURSARIES

1. Omuse Goffre Amuka (Kenya)
2. Scorza Manuela (Italy)
3. Surapaneni Krishna Mohan (India)



THE BINDING SITE BURSARIES

1. Giordano Sonia (Italy)
2. Kost Andriy (Ukraine)
3. Vilchez-Aguilera Juan Antonio (Spain)



THERMO FISHER BURSARIES

1. Albea Brenda (Argentina)
2. Begolli Gramos (Kosovo)
3. Chakraborty Sutirtha (India)
4. D'argenio Valeria (Italy)
5. Martínez-Villanueva Miriam (Spain)
6. Ntola Vuyolwethu Comfort (South Africa)
7. Wang Bei-Tzu (Taiwan)

RECIPIENTS

1. Brady Jennifer (Ireland)
2. Bugrov Alexey Viktorovich (Russia)
3. Depreter Barbara (Belgium)
4. González M. Santamaría (Spain)
5. Jacobs Leo (The Netherlands)
6. Jensen Christina Munch (Denmark)
7. Kovacevic Tamara (Serbia)
8. Lacevic Dzenana (Bosnia Herzegovina)
9. Mazeikiene Asta (Lithuania)
10. Mueller Daniel (Switzerland)
11. Paiva Teles Maria José (Portugal)
12. Poupouridou Nikoletta (Greece)
13. Simon Diána (Hungary)
14. Sonsala Alicja (Poland)
15. Sudmann Åshild Amelie (Norway)
16. Supak Smolcic Vesna (Croatia)
17. Tanrikulu Kucuk Sevda (Turkey)
18. Tingerides Alexis (Cyprus)
19. Vasatova Martina (Czech Republic)
20. Viikant Natali (Estonia)
21. Vuorenmaa Katariina (Finland)



THE BINDING SITE ITALIA AWARDS

WINNERS

- 1° ex-aequo: Lucia Paolini (Brescia, Italy)
Elena Zani (Bologna, Italy)
- 3°: Vittoria Barchiesi (Napoli, Italy)



IFCC-ROCHE TRAVEL SCHOLARSHIPS

1. Barbullushi Alma (Albania)
2. Chittamma Anchalee (Thailand)
3. Das Saswati (India)
4. Dayanath Bolonghoge (Sri Lanka)
5. Lumano Hilary (Zambia)
6. Mansour Neda Issa (Jordan)
7. Osegbe Ifeyinwa Dorothy (Nigeria)
8. Widodo Joko (Indonesia)



PHOTOGALLERY



1. The registration desk:
MZ Congressi Staff at work



2: A crowded exhibition area



3. IFCC
and EFLM booths

REPORTS FROM THE PRE-CONGRESS SATELLITE MEETINGS MAY, 18TH, 2013

The quality of molecular methods in the age of personalized medicine

Florence, Italy



Representatives of Scientific Societies acting in the area of Laboratory Medicine (IFCC, EFLM, ESPT, DGKL), of International organizations (CLSI, IRMM, CERM, EDMA, EAPM), and representatives of International Projects and Networks (SPIDIA, PHGEN, EUROAGENTEST, EMQN, APOGEE-Net/CanGeneTest, IMPACTS, ITT, GOIRC)



have presented at the Satellite Meeting their view on the role of Molecular Methods in Personalized Medicine and how to monitor the quality to allow the clinical use of these new diagnostics.

The meeting was attended by 38 participants.

Plasma proteins: from the basic to the optimal clinical application

Pavia, Italy

The aim of the meeting was to explore the world of plasma proteins from the basic to the clinical applications. In the first session the studies



from international experts on The Antibody Factory were illustrated; the second session explored the Inflammasomes in Health and in Disease". In the afternoon the Evidence-Based Applications for the use of cytokines and monoclonal gammopathy investigation were illustrated. The last session of the meeting was dedicated to the presentation of clinical cases and to their general discussion with the audience.

The meeting was attended by 87 participants who appreciated the presentations very much and actively participated to the discussion.

Fundamental in Porphyrrias

Luzern, Switzerland

Thanks to the Swiss Society of Clinical Chemistry that organized the Pre-Congress Satellite Meeting as the last topic of their Annual Assembly in the fascinating, historical city of Luzern, this event had an extraordinary attendance, with more than 400 persons, registered to learn more on this rare clinical condition. Most of them moved then to Milan by train for EuroMedLab main congress.

We would like to note that a group of young colleagues coming from Africa joined both the meeting of Luzern and the Congress in Milan. This is the evidence that close collaboration within Clinical Chemistry Societies always offers great opportunities to the laboratory world of young scientists.

The Pre-Congress Satellite Meetings were beautifully and efficiently organised by Biomedica



SEE YOU in ISTANBUL 2014 and PARIS 2015

IFCC WORLDLAB ISTANBUL 2014
22nd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC Worldlab 2014)
22nd Meeting of the Balkan Clinical Laboratory Federation (BCLF 2014)
26th National Congress of the Turkish Biochemical Society (TBS 2014)

22-26 June 2014
ISTANBUL, TURKEY
ISTANBUL CONGRESS CENTER

**EUROMEDLAB
PARIS 2015**
21-25 JUNE **SFBC**
REVOLUTION IN LABORATORY MEDICINE

21st IFCC - EFLM
European Congress of Clinical Chemistry
and Laboratory Medicine

EuroMedLab JIB - 2015 exhibition
22-24 June 2015

PARIS, FRANCE - Le Palais des Congrès
21-25 June 2015

The Congress President and the Congress Organising Committee wish to thank warmly all the Companies/Organisations listed below for their invaluable support

PLATINUM SPONSORS




GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS



SPONSORS

A. DE MORI
 A. MENARINI DIAGNOSTICS
 AB SCIEX
 ABAXIS EUROPE
 ABBOTT
 ADVANCED INSTRUMENTS
 ALIFAX
 AXIS-SHIELD / ALERE
 BECKMAN COULTER
 BECTON DICKINSON
 BIOKIT
 BIOMEDIA
 BIOMERIEUX
 BIOPORTO DIAGNOSTICS
 BIO-RAD LABORATORIES
 BIOSYSTEMS
 BPC BioSed
 BSN
 BÜHLMANN
 CELLAVISION AB
 CHROMSYSTEMS

CLONIT
 DAKO
 DGKL
 DIAGON
 DIAMOND DIAGNOSTICS
 DIASORIN
 DIASYS
 DIESSE
 DIRUI
 DRG
 ELGA LABWATER
 ELITECH GROUP
 EOS
 ERBA MANNHEIM
 EUROIMMUN
 GLP SYSTEMS
 GREINER BIO-ONE
 HEMOCUE AB
 HOLOGIC | Gen-Probe
 HORIBA MEDICAL
 IDS
 IMMUNDIAGNOSTIK
 INNOGENETICS

INOVA
 INSTRUMENTATION LABORATORY
 INTERLAB
 IRIS INTERNATIONAL
 LABQUALITY
 LTA
 MINDRAY MEDICAL INTERNATIONAL
 MITSUBISHI CHEMICAL EUROPE
 M-U-T
 NOEMALIFE
 NOVA BIOMEDICAL
 NOVATEC
 ORTHO CLINICAL DIAGNOSTICS
 PERKINELMER
 RADIOMETER MEDICAL
 RANDOX LABORATORIES
 R-BIOPHARM
 RECIPE
 ROCHE DIAGNOSTICS
 SACACE BIOTECHNOLOGIE
 SAMSUNG ELECTRONICS
 SARSTEDT
 SEBIA

SENTINEL
 SHENZHEN NEW INDUSTRIES
 BIOMEDICAL ENGINEERING
 SIEMENS HEALTHCARE DIAGNOSTICS
 STAGO
 STERIL FARMA
 SYSMEX EUROPE
 TECHNO MEDICA
 TERUMO EUROPE
 THE BINDING SITE
 THERMO FISHER SCIENTIFIC INC.
 THERMO FISHER SCIENTIFIC,
 IMMUNODIAGNOSTICS DIVISION,
 PHADIA
 TOSOH
 VACUTEST KIMA
 VELA DIAGNOSTICS
 WAKO CHEMICALS
 WATERS
 WEST MEDICA